Ontario Best Practices Research Initiative
Search for:
Home
News
About OBRI
OBRI Operations Team
Committees
OBRI Annual Report
Participating Rheumatologists
Sponsors
For Patients
Patient Information Sessions
Patient Newsletters
Point of Care Reports
OBRI Patient Advisory Committee
Lay Summaries
Data Collected
For Health Professionals
Data Management Reports
Investigator Newsletters
Site Tools & Forms
Site Request for Supplies
Procedure Manual
Publications
Posters
Presentations
Related Links
Contact Us
Discontinuation Rate of Tofacitinib is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients
By
OBRI Admin
|
Published
August 17, 2021
discontinuation-rate-of-tofacitinib-is-similar-when-compared-to-tnf-inhibitors-in-rheumatoid-arthritis-patients
Bookmark the
permalink
.
Comments are closed.